Amazon, Eli Lilly partner to deliver weight-loss drug Zepbound

Pharmaceutical giant Eli Lilly has joined forces with Amazon to streamline the delivery of weight-loss drug Zepbound directly to consumers’ doorsteps.

Lilly is expanding into direct-to-patient sales through LillyDirect, partnering with digital pharmacies TruePill and now Amazon Pharmacy.

In addition to weight-loss drugs, LillyDirect also provides access to medications for diabetes and migraines.

The collaboration, following Zepbound’s FDA approval in November, addresses the surging demand for weight-loss drugs, including Ozempic and Wegovy.

Zepbound is the drug tirzepatide and is administered via injection pen. It was previously branded as Mounjaro for diabetes and has been rebranded as Zepbound for weight loss.